Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for KORU Medical Systems, Inc. (NASDAQ: KRMD), a medical technology company focused on large-volume subcutaneous infusion solutions. These regulatory documents offer detailed information on the company’s operations, financial condition, risk factors, and material agreements related to its Freedom Syringe Infusion System and associated businesses.
Through its periodic reports, such as Form 10-K annual reports and Form 10-Q quarterly reports, KORU Medical discloses audited and interim financial statements, segment information for its core business and Pharma Services and Clinical Trials activities, and discussions of factors affecting demand for its subcutaneous infusion devices and services. These filings also describe the structure of the Freedom System, its regulatory status, and the company’s role in supporting large-volume subcutaneous drug delivery.
Form 8-K current reports document material events, including the public release of financial results, updated guidance, and key contracts. Recent 8-K filings have referenced press releases on preliminary and quarterly financial results and an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc., which covers the manufacture and supply of subassemblies, needle sets, and tubing products for KORU Medical.
Investors can also review proxy statements for information on executive compensation, equity awards, and corporate governance, as well as Form 4 insider transaction reports that show purchases, sales, or grants of KORU Medical common stock by directors and officers under the KRMD ticker.
On Stock Titan, KORU Medical’s SEC filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered tools can summarize lengthy filings such as 10-Ks and 10-Qs, highlight key sections on revenue drivers, manufacturing and supply arrangements, and non-GAAP metrics like adjusted EBITDA, and help users quickly locate discussions of regulatory submissions, pharma collaborations, and other factors relevant to KRMD’s subcutaneous infusion business.
KORU Medical Systems, Inc. reported that it has released a press release with certain preliminary financial results for the fiscal quarter and full year ended December 31, 2025. These figures are based on the company’s current estimates and may change after completion of its normal closing and review procedures. The details of the preliminary results are provided in the press release included as Exhibit 99.1. The company specifies that this information is being furnished rather than filed under securities laws, which affects how it is incorporated into other regulatory documents.
KORU Medical Systems, Inc.75,000 restricted stock units (RSUs)
One-fourth of the RSUs will vest on January 2, 202775,000 derivative securities$0 per unit
KORU Medical Systems, Inc. is registering shares of its common stock tied to an equity package for its incoming Chief Technology Officer, Eric Schiller. The filing covers 76,426 shares of restricted common stock and common stock issuable upon exercise of options covering 232,297 shares, all granted as a material inducement for him to accept the CTO role. These awards are subject to vesting and potential acceleration under individual agreements. The company also restates its standard provisions to limit director liability and to indemnify directors and officers to the maximum extent allowed under Delaware law and the federal securities laws.
KORU Medical Systems, Inc. (KRMD) reported an insider ownership update on a Form 4 filed by multiple reporting persons identified as a director and 10% owner. On 11/26/2025, a transaction coded "J(1)" involved the disposition of 41,000 shares of common stock at a stated price of $0. Following this transaction, the filer reports 5,830,335 shares of common stock beneficially owned indirectly through Horton Capital Partners Fund, LP, and an additional 517,200 shares of common stock beneficially owned directly. The filing includes customary disclaimers that it should not be construed as an admission of beneficial ownership or of any filing obligation.
KORU Medical Systems, Inc. entered into an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. on November 19, 2025. Effective as of January 1, 2024, the agreement replaces a prior manufacturing and supply agreement dated November 11, 2020.
Under the agreement, Command will manufacture and supply KORU’s subassemblies, needle sets and tubing products according to KORU’s specifications and purchase orders. The agreement runs through December 31, 2026 and automatically renews for one-year terms unless either party elects not to renew under its terms.
Either party may terminate the agreement for an uncured material breach within 45 days, upon the other party’s bankruptcy or insolvency, or as otherwise provided. The agreement also sets out terms for pricing and payment, rebates, purchase commitments based on KORU’s forecasts, and includes customary provisions covering delivery, inspection, warranties, quality management, business continuity, handling and transport, intellectual property, confidentiality and indemnification.
KORU Medical Systems (KRMD) reported Q3 2025 results with net revenues of $10.4 million, up 27.2% year over year. Core revenue reached $9.8 million (up 29.7%), driven by international core growth of 229.6%, while domestic core declined 5.0% due to ordering shifts and inventory reductions at a U.S. distributor.
Gross profit was $6.3 million, up 20.8%, with gross margin of 60.2% versus 63.4% a year ago, reflecting higher manufacturing costs, geographic mix, and tariff charges. Operating expenses were $7.1 million, modestly higher than last year. Net loss narrowed to $0.8 million from $1.6 million.
For the nine months, revenue was $30.2 million (up 21.9%) with a net loss of $2.2 million versus $4.5 million last year. Cash and cash equivalents were $8.5 million as of September 30, 2025, and there were no outstanding borrowings under the $5 million revolver or $5 million term facility. Management noted tariff-related charges of $0.1 million in Q3 and expects an annualized gross margin impact of less than 100 basis points.
KORU Medical Systems (KRMD) reported Q3 2025 results and updated its full‑year 2025 financial guidance via a press release furnished as Exhibit 99.1. The quarter covered the period ended September 30, 2025, and a conference call was scheduled for November 12, 2025 at 4:30 p.m. Eastern Time.
The company highlighted use of non‑GAAP measures, including adjusted EBITDA and adjusted diluted EPS, with definitions provided and reconciliations to GAAP included in the press release. Management views these metrics as helpful for comparing ongoing operations. The information under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities.
KORU Medical Systems (KRMD) reported an insider equity transaction. On 10/16/2025, the President and CEO was issued 29,463 shares of common stock at $4.08 per share under her employment agreement as the stock portion of the 2024 annual bonus (30% stock, 70% cash).
Following the transaction, she beneficially owned 1,052,626 shares. This includes 200,000 restricted stock awards that vest based on a market capitalization schedule prior to 3/15/27, and 600,000 restricted stock awards that vest based on net sales growth targets for fiscal years ended 12/31/22 through 12/31/25.
Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share. Following the transaction the reporting person beneficially owned 41,688 shares. The filing is a Form 4 statement of changes in beneficial ownership and was signed by Thomas Adams as attorney-in-fact.
KORU Medical Systems director Matin Shahriar reported a purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. Following this transaction the reporting person beneficially owns 91,520 shares. The filing was submitted on Form 4 and signed by an attorney-in-fact.